Literature DB >> 26488767

Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group.

Cindy Ke Zhou1, David P Check1, Joannie Lortet-Tieulent2, Mathieu Laversanne3, Ahmedin Jemal2, Jacques Ferlay3, Freddie Bray3, Michael B Cook1, Susan S Devesa1.   

Abstract

Prostate cancer is a significant public health burden and a major cause of morbidity and mortality among men worldwide. Analyzing geographic patterns and temporal trends may help identify high-risk populations, suggest the degree of PSA testing, and provide clues to etiology. We used incidence data available from the International Agency for Research on Cancer (IARC) and certain cancer registries for 43 populations across five continents during a median period of 24 years. Trends in overall prostate cancer rates showed five distinct patterns ranging from generally monotonic increases to peaking of rates followed by declines, which coincide somewhat with changes in the prevalence of PSA testing. Trends in age-specific rates generally mirrored those in the overall rates, with several notable exceptions. For populations where overall rates increased rapidly and then peaked, exemplified in North America and Oceania, the highest incidence tended to be most pronounced and occurred during earlier calendar years among older men compared with younger ones. For populations with almost continual increases in overall rates, exemplified in Eastern Europe and Asia, peaks were evident among men aged ≥ 75 years in many instances. Rates for ages 45-54 years did not clearly stabilize or decline in the majority of studied populations. Global geographic variation remained substantial for both overall and age-specific incidence rates regardless of levels of PSA testing, with the lowest rates consistently in Asia. Explanations for the persistent geographic differences and the continuing increases of especially early-onset prostate cancer remain unclear.
© 2015 UICC.

Entities:  

Keywords:  age-specific; incidence; international; prostatic neoplasms; trends

Mesh:

Year:  2015        PMID: 26488767      PMCID: PMC4712103          DOI: 10.1002/ijc.29894

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  44 in total

1.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2008-08-05       Impact factor: 25.391

2.  American Cancer Society guidelines for the early detection of cancer.

Authors:  Robert A Smith; Vilma Cokkinides; Andrew C von Eschenbach; Bernard Levin; Carmel Cohen; Carolyn D Runowicz; Stephen Sener; Debbie Saslow; Harmon J Eyre
Journal:  CA Cancer J Clin       Date:  2002 Jan-Feb       Impact factor: 508.702

Review 3.  Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales.

Authors:  J Chamberlain; J Melia; S Moss; J Brown
Journal:  Br J Urol       Date:  1997-05

4.  The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.

Authors:  J M Legler; E J Feuer; A L Potosky; R M Merrill; B S Kramer
Journal:  Cancer Causes Control       Date:  1998-10       Impact factor: 2.506

5.  Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.

Authors:  Michael W Drazer; Dezheng Huo; Mara A Schonberg; Aria Razmaria; Scott E Eggener
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

6.  Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers.

Authors:  C Mettlin; G Jones; H Averette; S B Gusberg; G P Murphy
Journal:  CA Cancer J Clin       Date:  1993 Jan-Feb       Impact factor: 508.702

7.  Graphical presentation of trends in rates.

Authors:  S S Devesa; J Donaldson; T Fears
Journal:  Am J Epidemiol       Date:  1995-02-15       Impact factor: 4.897

8.  Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.

Authors:  Rune Kvåle; Anssi Auvinen; Hans-Olov Adami; Asa Klint; Eivor Hernes; Bjørn Møller; Eero Pukkala; Hans H Storm; Laufey Tryggvadottir; Steinar Tretli; Rolf Wahlqvist; Elisabete Weiderpass; Freddie Bray
Journal:  J Natl Cancer Inst       Date:  2007-12-11       Impact factor: 13.506

9.  The role of increasing detection in the rising incidence of prostate cancer.

Authors:  A L Potosky; B A Miller; P C Albertsen; B S Kramer
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

10.  Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials.

Authors:  Elisabeth Eckersberger; Julia Finkelstein; Helen Sadri; Markus Margreiter; Samir S Taneja; Herbert Lepor; Bob Djavan
Journal:  Rev Urol       Date:  2009
View more
  88 in total

1.  Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?

Authors:  Morten Valberg; Tom Grotmol; Steinar Tretli; Marit B Veierød; Tron A Moger; Susan S Devesa; Odd O Aalen
Journal:  Eur J Epidemiol       Date:  2016-07-18       Impact factor: 8.082

2.  Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth.

Authors:  Gulzar Ahmad; Rana El Sadda; Galina Botchkina; Iwao Ojima; James Egan; Mansoor Amiji
Journal:  Cancer Lett       Date:  2017-08-11       Impact factor: 8.679

3.  Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.

Authors:  C Brooke Steele; Jun Li; Bin Huang; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

Review 4.  Epidemiology of Prostate and Testicular Cancer.

Authors:  Pauline Filippou; James E Ferguson; Matthew E Nielsen
Journal:  Semin Intervent Radiol       Date:  2016-09       Impact factor: 1.513

5.  The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer.

Authors:  Greg Dyson; Batoul Farran; Susan Bolton; Douglas B Craig; Alan Dombkowski; Jennifer L Beebe-Dimmer; Isaac J Powell; Izabela Podgorski; Lance K Heilbrun; Cathryn H Bock
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

6.  Data integration, analysis, and interpretation of eight academic CLARITY-BPA studies.

Authors:  Jerrold J Heindel; Scott Belcher; Jodi A Flaws; Gail S Prins; Shuk-Mei Ho; Jiude Mao; Heather B Patisaul; William Ricke; Cheryl S Rosenfeld; Ana M Soto; Frederick S Vom Saal; R Thomas Zoeller
Journal:  Reprod Toxicol       Date:  2020-07-16       Impact factor: 3.143

7.  Biodistribution and Pharmacokinetic Evaluations of a Novel Taxoid DHA-SBT-1214 in an Oil-in-Water Nanoemulsion Formulation in Naïve and Tumor-Bearing Mice.

Authors:  Gulzar Ahmad; Florence Gattacecca; Rana El Sadda; Galina Botchkina; Iwao Ojima; James Egan; Mansoor Amiji
Journal:  Pharm Res       Date:  2018-03-08       Impact factor: 4.200

8.  Association between radical prostatectomy and risk of herpes zoster.

Authors:  C-Y Hsu; P-R Chen; H-J Chen; J-A Liang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-18       Impact factor: 3.267

9.  Engaging African American Men as Citizen Scientists to Validate a Prostate Cancer Biomarker: Work-in-Progress.

Authors:  Karriem S Watson; Vida Henderson; Marcus Murray; Adam B Murphy; Josef Ben Levi; Tiffany McDowell; Alfreda Holloway-Beth; Pooja Gogana; Michael A Dixon; LeAndre Moore; Ivanhoe Hall; Alexander Kimbrough; Yamilé Molina; Robert A Winn
Journal:  Prog Community Health Partnersh       Date:  2019

10.  Laparoscopic major hepatectomy for hepatocellular carcinoma in elderly patients: a multicentric propensity score‑based analysis.

Authors:  Antonella Delvecchio; Maria Conticchio; Francesca Ratti; Maximiliano Gelli; Ferdinando Massimiliano Anelli; Alexis Laurent; Giulio Cesare Vitali; Paolo Magistri; Giacomo Assirati; Emanuele Felli; Taiga Wakabayashi; Patrick Pessaux; Tullio Piardi; Fabrizio Di Benedetto; Nicola de'Angelis; Javier Briceño-Delgado; Rene Adam; Daniel Cherqui; Luca Aldrighetti; Riccardo Memeo
Journal:  Surg Endosc       Date:  2020-08-03       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.